Why Amylyx is pulling ALS drug Relyvrio from US market after study
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Related articles
The government wants to buy their flood
HOUSTON (AP) — After the floodwaters earlier this month just about swallowed two of the six homes th2024-05-21Karen rebel forces attack stranded Myanmar junta troops on Thai border — Radio Free Asia
Gunfire, artillery and exploding bombs could we heard early Saturday around Myawaddy, a Myanmar city2024-05-21North Carolina's Harrison Ingram opts to enter the NBA draft
CHAPEL HILL, N.C. (AP) — North Carolina starting wing Harrison Ingram is entering the NBA draft.The2024-05-21Can US cities fine homeless people for sleeping outside?
WASHINGTON (AP) — The most significant case in decades on homelessness has reached the Supreme Court2024-05-21Company wins court ruling to continue development of Michigan factory serving EV industry
GREEN TOWNSHIP, Mich. (AP) — A judge has ordered a Michigan community to stop blocking efforts to br2024-05-21- MINNEAPOLIS (AP) — Minnesota Twins right-handed reliever Daniel Duarte will have season-ending elbow2024-05-21
atest comment